OTCMKTS:CLXPF

Cybin Competitors

$1.46
-0.02 (-1.35 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.38
Now: $1.46
$1.54
50-Day Range
$0.96
MA: $1.23
$1.55
52-Week Range
$0.49
Now: $1.46
$2.24
Volume196,740 shs
Average Volume443,996 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Cybin (OTCMKTS:CLXPF) Vs. DDXS, TNGN, ATTBF, ACHL, ADTX, and AGNPF

Should you be buying CLXPF stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Cybin, including (DDXS) (DDXS), (TNGN) (TNGN), Abattis Bioceuticals (ATTBF), Achilles Therapeutics plc American Depositary Shares (ACHL), ADiTx Therapeutics (ADTX), and Algernon Pharmaceuticals (AGNPF).

Cybin (OTCMKTS:CLXPF) and (DDXS) (OTCMKTS:DDXS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Cybin and (DDXS), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cybin00203.00
(DDXS)0000N/A

Profitability

This table compares Cybin and (DDXS)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CybinN/AN/AN/A
(DDXS)N/AN/AN/A

Earnings & Valuation

This table compares Cybin and (DDXS)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CybinN/AN/AN/AN/AN/A
(DDXS)N/AN/AN/AN/AN/A

Summary

Cybin beats (DDXS) on 1 of the 1 factors compared between the two stocks.

(TNGN) (OTCMKTS:TNGN) and Cybin (OTCMKTS:CLXPF) are both health technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for (TNGN) and Cybin, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(TNGN)0000N/A
Cybin00203.00

Profitability

This table compares (TNGN) and Cybin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(TNGN)N/AN/AN/A
CybinN/AN/AN/A

Earnings and Valuation

This table compares (TNGN) and Cybin's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(TNGN)N/AN/AN/AN/AN/A
CybinN/AN/AN/AN/AN/A

Summary

Cybin beats (TNGN) on 1 of the 1 factors compared between the two stocks.

Abattis Bioceuticals (OTCMKTS:ATTBF) and Cybin (OTCMKTS:CLXPF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Abattis Bioceuticals and Cybin, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abattis Bioceuticals0000N/A
Cybin00203.00

Profitability

This table compares Abattis Bioceuticals and Cybin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abattis BioceuticalsN/AN/AN/A
CybinN/AN/AN/A

Earnings and Valuation

This table compares Abattis Bioceuticals and Cybin's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abattis BioceuticalsN/AN/AN/AN/AN/A
CybinN/AN/AN/AN/AN/A

Summary

Cybin beats Abattis Bioceuticals on 1 of the 1 factors compared between the two stocks.

Achilles Therapeutics plc American Depositary Shares (NASDAQ:ACHL) and Cybin (OTCMKTS:CLXPF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Achilles Therapeutics plc American Depositary Shares and Cybin, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Achilles Therapeutics plc American Depositary Shares0000N/A
Cybin00203.00

Profitability

This table compares Achilles Therapeutics plc American Depositary Shares and Cybin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Achilles Therapeutics plc American Depositary SharesN/AN/AN/A
CybinN/AN/AN/A

Earnings and Valuation

This table compares Achilles Therapeutics plc American Depositary Shares and Cybin's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Achilles Therapeutics plc American Depositary SharesN/AN/AN/AN/AN/A
CybinN/AN/AN/AN/AN/A

Summary

Cybin beats Achilles Therapeutics plc American Depositary Shares on 1 of the 1 factors compared between the two stocks.

ADiTx Therapeutics (NASDAQ:ADTX) and Cybin (OTCMKTS:CLXPF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for ADiTx Therapeutics and Cybin, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADiTx Therapeutics00103.00
Cybin00203.00

Profitability

This table compares ADiTx Therapeutics and Cybin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADiTx TherapeuticsN/AN/AN/A
CybinN/AN/AN/A

Earnings and Valuation

This table compares ADiTx Therapeutics and Cybin's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADiTx TherapeuticsN/AN/AN/AN/AN/A
CybinN/AN/AN/AN/AN/A

Summary

Cybin beats ADiTx Therapeutics on 1 of the 1 factors compared between the two stocks.

Algernon Pharmaceuticals (OTCMKTS:AGNPF) and Cybin (OTCMKTS:CLXPF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Algernon Pharmaceuticals and Cybin, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Algernon Pharmaceuticals0000N/A
Cybin00203.00

Profitability

This table compares Algernon Pharmaceuticals and Cybin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Algernon PharmaceuticalsN/AN/AN/A
CybinN/AN/AN/A

Earnings and Valuation

This table compares Algernon Pharmaceuticals and Cybin's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Algernon PharmaceuticalsN/AN/AN/AN/AN/A
CybinN/AN/AN/AN/AN/A

Summary

Cybin beats Algernon Pharmaceuticals on 1 of the 1 factors compared between the two stocks.


Cybin Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
(DDXS) logo
DDXS
(DDXS)
0.5$0.00-0.0%$0.00N/A0.00
TNGN
(TNGN)
0.4N/AN/A$0.00N/A0.00Gap Up
Abattis Bioceuticals logo
ATTBF
Abattis Bioceuticals
0.4$0.02-0.0%$0.00N/A0.00Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.73-5.5%$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.81-2.8%$0.00N/A0.00
Algernon Pharmaceuticals logo
AGNPF
Algernon Pharmaceuticals
0.0$0.13-7.7%$0.00N/A0.00Increase in Short Interest
Gap Up
Almirall logo
LBTSF
Almirall
0.5$15.00-0.0%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08-0.0%$0.00N/A0.00
ARNI
Arno Therapeutics
0.5$0.01-23.1%$0.00N/A0.00Gap Up
ASCLF
Ascletis Pharma
0.4$0.37-0.0%$0.00N/A0.00News Coverage
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06-0.0%$0.00N/A0.00Increase in Short Interest
AXIM Biotechnologies logo
AXIM
AXIM Biotechnologies
0.4$0.60-3.3%$0.00N/A0.00
BXRXV
Baudax Bio
0.5N/AN/A$0.00N/A0.00High Trading Volume
BerGenBio ASA logo
BRRGF
BerGenBio ASA
0.7$3.52-0.0%$0.00N/A0.00
Cannabics Pharmaceuticals logo
CNBX
Cannabics Pharmaceuticals
0.4$0.22-0.0%$0.00N/A0.00High Trading Volume
Increase in Short Interest
Gap Up
ORHOF
CannaRoyalty
0.7$9.23-56.1%$0.00N/A0.00Gap Down
Cerebain Biotech logo
CBBT
Cerebain Biotech
0.0$0.04-0.0%$0.00N/A0.00Increase in Short Interest
Gap Up
CGYG
China Longyi Group International
0.4$0.00-0.0%$0.00N/A0.00
CLVLY
Clinuvel Pharmaceuticals
1.0$22.74-1.0%$0.00N/A0.00Decrease in Short Interest
CELZ
Creative Medical Technology
0.5$0.05-0.0%$0.00N/A0.00News Coverage
Eastgate Biotech logo
ETBI
Eastgate Biotech
0.5$0.00-0.0%$0.00N/A0.00
EMMBF
Emblem
0.6$1.40-1.4%$0.00N/A0.00
ENZC
Enzolytics
0.0$0.22-0.0%$0.00N/A0.00
GB Sciences logo
GBLX
GB Sciences
0.5$0.05-0.0%$0.00N/A0.00Increase in Short Interest
Gap Up
Genfit logo
GNFTF
Genfit
0.5$4.64-0.2%$0.00N/A0.00High Trading Volume
Decrease in Short Interest
News Coverage
GMXAY
GENMAB A/S/S
0.5$34.67-0.1%$0.00N/A0.00High Trading Volume
Genus logo
GENSF
Genus
0.7$69.40-0.0%$0.00N/A0.00High Trading Volume
Decrease in Short Interest
HALB
Halberd
0.0$0.04-0.0%$0.00N/A0.00Gap Down
HAVN Life Sciences logo
HAVLF
HAVN Life Sciences
0.0$0.59-1.3%$0.00N/A0.00Decrease in Short Interest
Idorsia logo
IDRSF
Idorsia
0.5$27.18-0.0%$0.00N/A0.00
IPATF
ImmunoPrecise Antibodies
0.5N/AN/A$0.00N/A0.00High Trading Volume
IMLFF
InMed Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Innovation Pharmaceuticals logo
IPIX
Innovation Pharmaceuticals
0.6$0.26-3.9%$0.00N/A0.00News Coverage
Kalytera Therapeutics logo
KALTF
Kalytera Therapeutics
0.6$0.06-36.4%$0.00N/A0.00Increase in Short Interest
Gap Down
Medican Enterprises logo
MDCN
Medican Enterprises
0.5$0.00-0.0%$0.00N/A0.00Decrease in Short Interest
Gap Down
Mesoblast logo
MEOBF
Mesoblast
0.5$1.72-0.0%$0.00N/A0.00Gap Down
MCURF
Mind Cure Health
0.0$0.35-0.0%$0.00N/A0.00Increase in Short Interest
Mind Medicine (MindMed) logo
MMEDF
Mind Medicine (MindMed)
1.1$2.43-3.7%$0.00N/A0.00
Molecular Partners logo
MLLCF
Molecular Partners
0.5$24.78-1.9%$0.00N/A0.00Gap Down
MPSYF
MorphoSys
0.0$90.50-2.6%$0.00N/A0.00News Coverage
Gap Down
NRNVF
Nordic Nanovector ASA
0.0$1.64-0.0%$0.00N/A0.00High Trading Volume
Novozymes A/S logo
NVZMF
Novozymes A/S
0.4$66.85-2.4%$0.00N/A0.00Gap Down
BPSR
Organicell Regenerative Medicine
0.5$0.06-0.0%$0.00N/A0.00Increase in Short Interest
News Coverage
Oxurion logo
TBGNF
Oxurion
0.5$2.75-0.0%$0.00N/A0.00
Pharnext logo
PNEXF
Pharnext
0.0$4.11-0.0%$0.00N/A0.00Decrease in Short Interest
PTEO
Proteo
0.5$0.09-0.0%$0.00N/A0.00
PROT
Proteonomix
0.5$0.01-0.0%$0.00N/A0.00Increase in Short Interest
Gap Down
ProtoKinetix logo
PKTX
ProtoKinetix
0.5$0.18-44.4%$0.00N/A0.00High Trading Volume
Decrease in Short Interest
News Coverage
Gap Up
PureTech Health logo
PTCHF
PureTech Health
0.0$5.64-1.9%$0.00N/A0.00Decrease in Short Interest
RCPHF
Recipharm AB (publ)
1.0$16.05-0.0%$0.00N/A0.00High Trading Volume
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.